WHAT PROBIOTIC SHOULD I **RECOMMEND TO MY PATIENT?**

Clinical Guide to Probiotic Products in Canada

Dragana Skokovic-Sunjic BScPhm RPh NCMP Clinical Pharmacist, Hamilton FHT Author, Clinical Guide for Probiotic Products Available in Canada



Presenter's Name: Dragana Skokovic-Sunjic I have no potential or perceived conflict of interest I have the Relationships with commercial interests: AEProbio (Alliance for Education in Probiotics): Author, Advisory Board member

Presenter Disclosure



• This program has received no financial or in-kind support from any commercial or other organization


COMMERCIAL SUPPORT DISCLOSURE



Definition: "live microorganisms which when administered in adequate amounts confer a health benefit on the host"

Ref: FAO/WHO (2002) Joint Working Group Guidelines for Probiotics in Food Photo credit: http://insertmedia.office.microsoft.com Archens Bacteria prokaryotic(onecelledorganism)Sponges

PROBIOTICS : DEFINITION





OLD Definition: "live microorganisms which when administered in adequate amounts confer a health benefit on the host"

NEW definition: "live microorganisms that, when administered in adequate amounts, confer a health benefit on the host"

Hill, C. ISAPP consensus on the probiotic concept, Gut Microbiota for Health World Summit, Barcelona March 2015

PROBIOTICS : DEFINITION




OPEN

EXPERT CONSENSUS DOCUMENT The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic

Colin Hill, Francisco Guarner, Gregor Reid, Glenn R. Gibson, Daniel J. Merenstein, Bruno Pot, Lorenzo Morelli, Roberto Berni Canani, Harry J. Flint, Seppo Salminen, Philip C. Calder and Mary Ellen Sanders 506 AUGUST 2014 VOLUME 11

Hill, C. ISAPP consensus on the probiotic concept, Gut Microbiota for Health World Summit, Barcelona March 2015



CONSENSUS STATEMENTS


Let's eat grandpa. Let's eat, grandpa.






CLINICAL RESEARCH IS EXPANDING Search keywords: probiotics, clinical study, English language







Source: Monica Feldman, Head of Industry Research, Euromonitor Int'l, Probiota Americas 2015, June 2015


CONSUMER INTEREST IN PROBIOTICS



• Science

Popular demand

WHY IS THERE DISCONNECT?







WHAT DOES OUR PATIENT SEE ON THE SHELF?



Photo: curtesy Iris Kracwchenko RPh

Probiotics: A Consumer Guide for Making Smart Choices, Developed by Int Assoc for Probiotics and Prebiotics, March 2009

HOW TO RECOGNIZE A TRUE PROBIOTIC

- Quality of the strain(s) of probiotic <u>Synergy</u> of the microorganisms, if in combination
- Guaranteed bioactivity, i.e. live and healthy microorganisms able to carry on the probiotic activity
- Protective environment: Microorganisms can provide maximum activity at the site of action
- Clinical research on the finished product has been conducted for efficacy and safety



DO PRODUCTS WITH MANY STRAINS PROVIDE ENHANCED BENEFITS ?

Adding extra strains to a proven formulation does not necessarily make it better (may interfere with the proven activity) • Clinical benefits have to be proven for particular mixture • Some strains are not recommended for human use

ISAPP (International Scientific Association for Probiotics and Prebiotics, 2009 Report





• Calculated in CFU (colony-forming units) • Not possible to determine a general dose for all probiotics Must be based on human studies showing a health benefit • Varies greatly depending on strain and product

ISAPP (International Scientific Association for Probiotics and Prebiotics, 2009 Report

DOES A HIGHER DOSE OF PROBIOTIC PROVIDE ENHANCED BENEFITS ?



STRAIN **CNCM I-2494** 35624 **HA111 DSM 17938 CL1285** LBC80R CLR2 **CNCM I-1518** lyo Several strains 299v Several defined strains **BB-12**

Some commercially available products in Canada **GENUS & SPECIES** Lactobacillus rhamnosus

Bifidobacterium lactis Bifidobacterium infantis

Lactobacillus reuteri

Lactobacillus acidophilus Lactobacillus casei

Lactobacillus rhamnosus

Lactobacillus casei


Saccharomyces boulardii

Several genus and species Lactobacillus plantarum

Several genus and species

Bifidobacterium lactis Lactobacillus acidophilus

- **LA-5**



BRAND Activia Align Bacid Biogaia

Bio-K

DanActive

Florastor

Probaclac

TuZen

VSL#3


Yoptimal

CLASSIFICATION OF BACTERIA (documentation on strain level required)


Genus

Species


Strain



Lactobacillus



ATCC PTA 5289







Genus

Species

Strain

CLASSIFICATION OF BACTERIA Is the strain really important? Homo sapiens Healthcare professional Wayne Gretzky Dr. Oz Dragana








Health Canada has adopted the FAO/WHO definition of probiotics • Probiotics can fall under the *Food* or *Natural Health* Product categories

Health Canada website for approved claims: NHP: http://www.hc-sc.gc.ca/dhp-mps/prodnatur/index-eng.php Food: http://www.hc-sc.gc.ca/fn-an/label-etiquet/claims-reclam/probiotics claimsallegations probiotiques-eng.php

CANADIAN REGULATIONS







Search tools

Search tools


Search tools

Clinical Guide to Probiotic Supplements Available in Canada: 2015 Edition Indications, Dosage Forms, and Clinical Evidence to Date

Author: Dragana Skokovic-Sunjic BScPhm RPh NCMP

This Guide is designed to translate scientific evidence available for probiotic supplements to practical, clinically relevant information, enabling clinicians to easily select the appropriate product, dose, and format for a specific indication.

THE PURPOSE OF THIS PROJECT






 Project started in 2008 when a gap in translating knowledge on probiotic supplements was identified • The first version of the Clinical Guide was reviewed and distributed to primary care physicians and allied health care professionals in Canada in 2009. • This document is updated annually for new products, indications, and evidence, with the Expert Advisory Board of reviewers expanding as well to include a variety of specializations.

THE HISTORY OF THE PROJECT







product.


NETHODS Published data/ studies with defined clinical outcome for probiotic strain(s) was searched, using inclusion criteria as listed on the Guide Commercially available products containing said

- strain(s) were identified
- The inclusion criteria was used to evaluate the strength of the recommendation for each
- Once this information was compiled into a comprehensive chart form, it was assessed by independent expert reviewers.





MEDICAL EDITOR



MEET THE TEAM BEHIND THE CLINICAL GUIDE:

Ivana Sunjic, MSc Universiteit Antwerpen (Belgium), University of Guelph (Canada)



ADVISORY BOARD OF EXPERT REVIEWERS:











Dr. Vivien Brown, MDCM, CCFP, FCFP, NCMP President of the Federation of Medical Women of Canada Vice-President of Medical Affairs, Medisys Health Group

Clinical Epidemiologist, Anesthesia and Pain Medicine - The Hospital for Sick Children Scientist, Child Health Evaluative Sciences - Research Institute Assistant Professor, Institute for Health Policy, Management and Evaluation - University of Toronto Assistant Professor, Department of Clinical Epidemiology & Biostatistics - McMaster University

Iris Krawchenko, BSc Phm **Clinical Pharmacist - Hamilton Family Health Team** Pharmacist Educator, Consultant – Canada Pharmacy Council Canadian Pharmacists Association, Ontario Board Member

Dr. John Marshall, MD MSc FRCPC AGAF Professor, Department of Medicine, McMaster University, Hamilton Member, Farncombe Family Digestive Health Research Institute Head, Clinical Research for the Division of Gastroenterology - Hamilton

Pharmacist Health Educator Consultant to Primary Care Family Health Team Action Group as appointed by the Ontario Ministry of Health

Dr. Bradley Johnston, PhD, PDF

Dr. Tom Smiley, BScPhm, PharmD

- Note:

INCLUSION CRITERIA:

1. Commercially available in Canada as a supplement or probiotic-containing functional food 2. Approved by Health Canada (NPN) for probiotic supplements (tablets, capsules, sachets) 3. Published clinical evidence for the particular strain(s) present in each product/food

changes in the strains used

- For products containing multiple strains, evidence must be for the specific combination and not for the separate probiotic strains - Some products are excluded from the current edition due to





ACRON	YMS /INDICATIO	
AAD	Antibiotic associated diarrhea - Prevention	E
CD-PP	<i>Clostridium difficile</i> associated diarrhea - Primary prevention	(
HP	Helicobacter pylori - Adjunct to standard eradication therapy	
IBS	Irritable bowel syndrome	
PD	Periodontal disease	F (

NS				
BG	Reduces blood glucose in Type II Diabetes (FBG and HA1c)		Constipation	
CE/AE	Childhood eczema / Atopic dermatitis		Common infectious disease	FAP
ID	Infectious diarrhea		Inflammatory bowel disease - Pouchitis	IBD-UC
LDL-C	Reduces LDL and total cholesterol		Necrotizing Enterocolitis (newborn) *as per hospital protocol, not for self- administration	
	Reduces regurgitation/ Improves gastrointestinal motility	TD	Traveler's diarrhea	CFU
				s y m i

Clostridium difficile associated diarrhea -Prevention

Functional abdominal pain

C IBD - Ulcerative colitis - Adjunct to standard therapy

Nosocomial infections prevention

Colony forming units (number of viable bacteria)



Level I: (HIGHEST LEVEL) Level II:

- Evidence obtained from well-designed controlled trials without randomization/ - Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group/ - Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled trials might also be regarded as this type of evidence. Level III:

 Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.

LEVELS OF EVIDENCE:

- Evidence obtained from at least one properly designed randomized trial.



INDICATIONS FOR ADULT HEALTH																
Brand Name	Probiotic Strain (s)	Dosage Form	CFU/dose	No. of doses/day	ID	AAD	CDAD CD-PP	TD	С	IBS	IBD- UC	IBD-P	HP	PD	LDL-C	CID
Align™	B. longum infantis 35624	Capsules	1B/capsule	1 capsule						 1-3						
BioGaia [®] drops举 BioGaia [®] chew tabs	<i>L. reuteri protectis</i> DSM 17938	Drops Chew. tabs	100M/5drops 100M/tab	5 drops 1 tab	114	II ⁵							J 6-9			
Bio-K+ CL1285≉	<i>L. acidophilus</i> CL 1285	Regular Capsule Strong Capsule "Travel Protection" Extra Strength	12.5B/capsule 25B/capsule 30B/capsule 50B/capsule	1-2 capsules		I 10-12	10-12 11,13 a 13,14 a									
	Ferm. rice lq. 50B/tub Ferm, soy lq	½ -1 tub														
Cardioviva TM	<i>L. reuteri</i> NCIMB 30242	Capsule	2B/capsule	2 capsules											 15-17	
Culturelle®	<i>L. rhamnosus</i> GG	Capsule	10B/capsule	1 capsule		 18							 19			
Florastor®	Saccharomyces boulardii lyo	Capsule Sachet	5B/capsule 5B/sachet	1-2 capsules 1-2 sachets		J 20, 21	13, 21, 22 13, 14	 23-25			III ²⁶		 27-29			
Mutaflor® 举	<i>Echerichia coli</i> Nissle 1917	Capsule	2.5- 25B/capsule	1-2 capsules							 30-33					
PerioBalance™	<i>L. reuteri prodentis</i> (ATCC 55730 and ATCC PTA 5289)	Lozenge	100M each/lozenge	2 lozenges										 ^{34, 35}		
Proxiflor® (formerly Lacidofil)	<i>L. rhamnosus</i> R0011 <i>L. helveticus</i> R0052	Capsule	4B/capsule	1-3 capsules						III ³⁶						
TuZen®	<i>L. plantarum</i> 299v	Capsule	10B/capsule	1-2 capsules		III ³⁷	III ³⁸			I 39-41						
UltraFlora [™] Cold Support (formerly Health Defense)	<i>L. plantarum</i> HEAL9	Capsule	0.5B each/capsule	1 capsule												J 42,43
VSL#3® 举	 L. acidophilus SD5212 B longum SD5219 L. casei SD5218 B. infantis SD5220 L. bulgaricus B. breve SD5206 SD5210 S. thermophilus L. plantarum SD5209 	Sachet	450B/sachet	1-4 sachets					II 44		J 45-47	J46, 48- 50				

INDICATIONS FOR PEDIATRIC HEALTH																	
Brand Name	Probiotic Strain (s)	Dosage Form	CFU/dose	No. doses /day	Regurg/ GI Mot	NEC* (newb orn)	Colic	ID	AAD	CDAD	IBD- UC	HP	С	IBS/ FAP	CID	NI	CE/AD
BioGaia [®] drops举 BioGaia [®] chew tabs	<i>L. reuteri protectis</i> DSM 17938	Drops Chew. tabs	100M/5drops 100M/tab	5 drops 1 tab	J51,52,53* Preterm infants *full tem infants	J 54	J 55-58	J 59-63	J 64				J 65,66	J 67,68	J 69,70		II 71
Culturelle®	<i>L. rhamnosus</i> GG	Powder	1B/packet	6-10 packets				J 72-77	J 78,79					 80,81		 82* *> 12yo	J 83-89
FloraBABY 举	 B. breve HA-129 1.2B L. rhamnosus HA-111 1B B. bifidum HA-132 0.8B B. bifidum HA-132 0.4B 	Powder	4B/scoop	1 scoop		I I90											
Florastor®	Saccharomyces boulardii Iyo	Capsule Sachet	5B/capsule 5B/sachet	1-2 capsules 1-2 sachets				 91-93	J 94	III 95		II ²⁸					
Junior Daily Probiotic (formerly DDS® Junior)	<i>B. lactis</i> UABLA-12 4.2B <i>L. acidophilus</i> DDS®-1 0.8B	Powder	5B/gram	2 grams											II 96		J 97
Proxiflor® (formerly Lacidofil)	<i>L. rhamnosus</i> R0011 3.8B <i>L.helveticus</i> R0052 0.2B	Capsule	4B/capsule	1 capsule													II 98
UltraFlora [™] Children's	<i>L. acidophilus</i> NCFM® <i>B. animalis subsp lactis</i> Bi-07	Chewable tablet	2.5B each/chewabl e tablet	1-2 chew. tablets											 99		
VSL#3*	 L. acidophilus SD5212 L. casei SD5218 L. bulgaricus SD5210 L. plantarum SD5209 B. longum SD5219 B. infantis SD5220 B. breve SD5206 S. thermophilus SD5207 	Sachet	450B/sachet	1-2 sachets				J 100			 101,102			J 103			

INDICATIONS FOR PEDIATRIC HEALTH



Brand Name	Probiotic Strain (s)	Dosage Form	CFU per dose	No. of doses / day	Vulvovaginal candidiasis	Bacterial vaginosis
ProB [™] (RePhresh ProB) and Fem-Dophilus®	<i>L. rhamnosus</i> GR-1 <i>L. reuteri</i> RC-14	Oral capsule	2.5B each/capsule	1 capsule	J 104,105	J106-108
Probaclac BV®	<i>L. acidophilus</i> A-212 0.4B <i>L. rhamnosus</i> A-119 6.8B <i>S. thermophilus</i> A-336 0.8B	Vaginal capsule	8B/capsule	1-2 capsules		ll103
Provacare TM	<i>L. rhamnosus</i> Lcr35	Vaginal capsule	3.41B/capsule	2 capsules	 110	 111-113
Purfem TM	<i>L. rhamnosus</i> PBO1, <i>L. gasseri</i> EN-153471 (EBO1)	Vaginal ovule	1B each/ovule	1 ovule		J 114,115
UltraFlora TM Women's	<i>L. reuteri</i> RC-14 <i>L. rhamnosus</i> GR-1	Oral capsule	1B each/capsule	2 capsules	J 116	 117,118

INDICATIONS FOR VAGINAL HEALTH





		Dosage Form (CFU)	No. of doses /		Chil	dren		Adults						
Brand Name	Probiotic Strain (s)	At the time of packaging	day	ID	HP	AAD	CID	AAD	IBS	HP	C	BG		
Activia® 🕸	<i>B. lactis</i> CNCM I-2494 (formerly DN-173 010)	1B/serving	1-3 servings						 119,120		 121			
DanActive [®] 举	<i>L. casei sp. paracasei</i> CNCM I- 1518 (formerly DN-114 001)	10B/serving	1-2 servings	II ¹²²⁻¹²⁴	II ¹²⁵		J 126	 127						
Nestlé [®] Gerber [®]		1B/28 g serving	1 serving			1 128,129	1 28,129							
Infant Cereals		ID/20 g Serving	TSELVING											
Nestlé [®] Gerber [®]		1B/35 g serving	1 serving			1 128,129	128,129							
Toddler Cereals		TD/33 g serving	TSELVING											
Nestlé [®] Gerber [®]	<i>B. lactis</i> BB-12 DSM 10140													
Graduates Toddler		1B/200mL serving	1 serving			 128,129	9 128,129							
Drink														
Nestlé [®] Good Start [®] Probiotic Infant Formula		130 M/100mL serving	Routine feeding if an alternative to breast milk is required			J 130								
Yoptimal® and iOGO Probio [™]	<i>B. lactis</i> BB-12 <i>L. acidophilus</i> LA-5	1B/100g	1-3 servings							131-134	J135,136	II 137		

FUNCTIONAL FOODS WITH ADDED PROBIOTICS



Thanks to support by AEP members (*Alliance for Education in Probiotic*)







Clinical Guide is available online at: www.probioticguide.ca

Available as **PROBIOTIC** mobile app





There is an emerging role of probiotics in prevention and treatment



Not all probiotics are created equal or offer the same level of clinical evidence

CONCLUSIONS




Photo: Microsoft clipart



PRACTICE PEARLS

Recommendation should be based on: Demonstrated efficacy for specific indication **V** Defined **strain** of bacteria Correct dose for a specific condition Quality product that abides by the principles of Good Manufacturing Processes





Photo: private collection

THANK YOU

